Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Stühmer T[au]:

Search results

Items: 1 to 50 of 52

1.

RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS.

Seibold M, Stühmer T, Kremer N, Mottok A, Scholz CJ, Schlosser A, Leich E, Holzgrabe U, Brünnert D, Barrio S, Kortüm KM, Solimando AG, Chatterjee M, Einsele H, Rosenwald A, Bargou RC, Steinbrunn T.

Haematologica. 2019 Oct 10. pii: haematol.2019.223024. doi: 10.3324/haematol.2019.223024. [Epub ahead of print]

2.

IKZF1/3 and CRL4-CRBN E3 ubiquitin ligase mutations and IMiD resistance in multiple myeloma.

Barrio S, Munawar U, Zhu YX, Giesen N, Shi CX, Da Viá M, Sanchez R, Bruins L, Demler T, Müller N, Haertle L, Garitano A, Steinbrunn T, Danhof S, Cuenca I, Barrio-Garcia C, Braggio E, Rosenwald A, Martinez-Lopez J, Rasche L, Raab MS, Stewart AK, Einsele H, Stühmer T, Kortüm KM.

Haematologica. 2019 Sep 26. pii: haematol.2019.217943. doi: 10.3324/haematol.2019.217943. [Epub ahead of print]

3.

The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1+ subgroup of multiple myeloma cells for TNF-induced cell death.

El-Mesery M, Rosenthal T, Rauert-Wunderlich H, Schreder M, Stühmer T, Leich E, Schlosser A, Ehrenschwender M, Wajant H, Siegmund D.

Cell Death Dis. 2019 Aug 13;10(8):611. doi: 10.1038/s41419-019-1860-2.

4.

Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness.

Munawar U, Rasche L, Müller N, Vogt C, Da-Via M, Haertle L, Arampatzi P, Dietrich S, Roth M, Garitano-Trojaola A, Steinhardt MJ, Strifler S, Gallardo M, Martinez-Lopez J, Bargou RC, Heckel T, Einsele H, Stühmer T, Kortüm KM, Barrio S.

Blood. 2019 Sep 5;134(10):836-840. doi: 10.1182/blood.2019000080. Epub 2019 Jul 24. No abstract available.

PMID:
31340981
5.

Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.

Brünnert D, Kraus M, Stühmer T, Kirner S, Heiden R, Goyal P, Driessen C, Bargou RC, Chatterjee M.

Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1666-1676. doi: 10.1016/j.bbadis.2019.04.003. Epub 2019 Apr 4.

PMID:
30954557
6.

A simple approach for multi-targeted shRNA-mediated inducible knockdowns using Sleeping Beauty vectors.

Fink S, Zugelder L, Roth B, Brandt E, Meloche S, Izsvák Z, Bargou RC, Stühmer T.

PLoS One. 2018 Oct 19;13(10):e0205585. doi: 10.1371/journal.pone.0205585. eCollection 2018.

7.

Spectrum and functional validation of PSMB5 mutations in multiple myeloma.

Barrio S, Stühmer T, Da-Viá M, Barrio-Garcia C, Lehners N, Besse A, Cuenca I, Garitano-Trojaola A, Fink S, Leich E, Chatterjee M, Driessen C, Martinez-Lopez J, Rosenwald A, Beckmann R, Bargou RC, Braggio E, Stewart AK, Raab MS, Einsele H, Kortüm KM.

Leukemia. 2019 Feb;33(2):447-456. doi: 10.1038/s41375-018-0216-8. Epub 2018 Jul 19.

PMID:
30026573
8.

Protocol for M3P: A Comprehensive and Clinical Oriented Targeted Sequencing Panel for Routine Molecular Analysis in Multiple Myeloma.

Barrio S, DáVia M, Bruins L, Stühmer T, Steinbrunn T, Bittrich M, Einsele H, Stewart AK, Braggio E, Kortüm KM.

Methods Mol Biol. 2018;1792:117-128. doi: 10.1007/978-1-4939-7865-6_8.

PMID:
29797255
9.

JAM-A as a prognostic factor and new therapeutic target in multiple myeloma.

Solimando AG, Brandl A, Mattenheimer K, Graf C, Ritz M, Ruckdeschel A, Stühmer T, Mokhtari Z, Rudelius M, Dotterweich J, Bittrich M, Desantis V, Ebert R, Trerotoli P, Frassanito MA, Rosenwald A, Vacca A, Einsele H, Jakob F, Beilhack A.

Leukemia. 2018 Mar;32(3):736-743. doi: 10.1038/leu.2017.287. Epub 2017 Sep 28.

10.

The anti-myeloma activity of bone morphogenetic protein 2 predominantly relies on the induction of growth arrest and is apoptosis-independent.

Lagler C, El-Mesery M, Kübler AC, Müller-Richter UDA, Stühmer T, Nickel J, Müller TD, Wajant H, Seher A.

PLoS One. 2017 Oct 13;12(10):e0185720. doi: 10.1371/journal.pone.0185720. eCollection 2017.

11.

Utilizing BMP-2 muteins for treatment of multiple myeloma.

Seher A, Lagler C, Stühmer T, Müller-Richter UDA, Kübler AC, Sebald W, Müller TD, Nickel J.

PLoS One. 2017 May 10;12(5):e0174884. doi: 10.1371/journal.pone.0174884. eCollection 2017.

12.

Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma.

Keppler S, Weiβbach S, Langer C, Knop S, Pischimarov J, Kull M, Stühmer T, Steinbrunn T, Bargou R, Einsele H, Rosenwald A, Leich E.

Oncotarget. 2016 Jun 21;7(25):38762-38774. doi: 10.18632/oncotarget.9607.

13.

Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.

Müller E, Bauer S, Stühmer T, Mottok A, Scholz CJ, Steinbrunn T, Brünnert D, Brandl A, Schraud H, Kreßmann S, Beilhack A, Rosenwald A, Bargou RC, Chatterjee M.

Leukemia. 2017 Apr;31(4):922-933. doi: 10.1038/leu.2016.264. Epub 2016 Sep 30.

PMID:
27686868
14.

Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines.

Hausmann S, Brandt E, Köchel C, Einsele H, Bargou RC, Seggewiss-Bernhardt R, Stühmer T.

PLoS One. 2015 Apr 2;10(4):e0122689. doi: 10.1371/journal.pone.0122689. eCollection 2015.

15.

MLN4924 sensitizes monocytes and maturing dendritic cells for TNF-dependent and -independent necroptosis.

El-Mesery M, Seher A, Stühmer T, Siegmund D, Wajant H.

Br J Pharmacol. 2015 Mar;172(5):1222-36. doi: 10.1111/bph.12998. Epub 2015 Jan 13.

16.

Efficient transient transfection of human multiple myeloma cells by electroporation--an appraisal.

Steinbrunn T, Chatterjee M, Bargou RC, Stühmer T.

PLoS One. 2014 Jun 5;9(6):e97443. doi: 10.1371/journal.pone.0097443. eCollection 2014.

17.

PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform.

Hofmann C, Stühmer T, Schmiedl N, Wetzker R, Mottok A, Rosenwald A, Langer C, Zovko J, Chatterjee M, Einsele H, Bargou RC, Steinbrunn T.

Br J Haematol. 2014 Aug;166(4):529-39. doi: 10.1111/bjh.12920. Epub 2014 Apr 26.

PMID:
24766330
18.

Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.

Jungkunz-Stier I, Zekl M, Stühmer T, Einsele H, Seggewiss-Bernhardt R.

Leuk Lymphoma. 2014 Jan;55(1):168-76. doi: 10.3109/10428194.2013.794270. Epub 2013 Jun 3.

PMID:
23573828
19.

The IKK inhibitor Bay 11-7082 induces cell death independent from inhibition of activation of NFκB transcription factors.

Rauert-Wunderlich H, Siegmund D, Maier E, Giner T, Bargou RC, Wajant H, Stühmer T.

PLoS One. 2013;8(3):e59292. doi: 10.1371/journal.pone.0059292. Epub 2013 Mar 20.

20.

Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules.

Leich E, Weißbach S, Klein HU, Grieb T, Pischimarov J, Stühmer T, Chatterjee M, Steinbrunn T, Langer C, Eilers M, Knop S, Einsele H, Bargou R, Rosenwald A.

Blood Cancer J. 2013 Feb 8;3:e102. doi: 10.1038/bcj.2012.47.

21.

The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma.

Heimberger T, Andrulis M, Riedel S, Stühmer T, Schraud H, Beilhack A, Bumm T, Bogen B, Einsele H, Bargou RC, Chatterjee M.

Br J Haematol. 2013 Feb;160(4):465-76. doi: 10.1111/bjh.12164. Epub 2012 Dec 18.

PMID:
23252346
22.

The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma.

Chatterjee M, Andrulis M, Stühmer T, Müller E, Hofmann C, Steinbrunn T, Heimberger T, Schraud H, Kressmann S, Einsele H, Bargou RC.

Haematologica. 2013 Jul;98(7):1132-41. doi: 10.3324/haematol.2012.066175. Epub 2012 Oct 12.

23.

Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.

Steinbrunn T, Stühmer T, Sayehli C, Chatterjee M, Einsele H, Bargou RC.

Br J Haematol. 2012 Nov;159(4):430-40. doi: 10.1111/bjh.12039. Epub 2012 Sep 17.

PMID:
22985491
24.

Integrin-linked kinase is dispensable for multiple myeloma cell survival.

Steinbrunn T, Siegmund D, Andrulis M, Grella E, Kortüm M, Einsele H, Wajant H, Bargou RC, Stühmer T.

Leuk Res. 2012 Sep;36(9):1165-71. doi: 10.1016/j.leukres.2012.05.005. Epub 2012 Jun 1.

PMID:
22658851
25.

Preclinical activity of the novel orally bioavailable HSP90 inhibitor NVP-HSP990 against multiple myeloma cells.

Stühmer T, Iskandarov K, Gao Z, Bumm T, Grella E, Jensen MR, Einsele H, Chatterjee M, Bargou RC.

Anticancer Res. 2012 Feb;32(2):453-62.

PMID:
22287732
26.

TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms.

Rauert H, Stühmer T, Bargou R, Wajant H, Siegmund D.

Cell Death Dis. 2011 Aug 18;2:e194. doi: 10.1038/cddis.2011.78.

27.

Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.

Fagerli UM, Ullrich K, Stühmer T, Holien T, Köchert K, Holt RU, Bruland O, Chatterjee M, Nogai H, Lenz G, Shaughnessy JD Jr, Mathas S, Sundan A, Bargou RC, Dörken B, Børset M, Janz M.

Oncogene. 2011 Jul 14;30(28):3198-206. doi: 10.1038/onc.2011.79. Epub 2011 Apr 11.

PMID:
21478911
28.

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival.

Steinbrunn T, Stühmer T, Gattenlöhner S, Rosenwald A, Mottok A, Unzicker C, Einsele H, Chatterjee M, Bargou RC.

Blood. 2011 Feb 10;117(6):1998-2004. doi: 10.1182/blood-2010-05-284422. Epub 2010 Dec 13.

PMID:
21149634
29.

Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.

Stingl L, Stühmer T, Chatterjee M, Jensen MR, Flentje M, Djuzenova CS.

Br J Cancer. 2010 May 25;102(11):1578-91. doi: 10.1038/sj.bjc.6605683.

30.

Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585.

Stühmer T, Arts J, Chatterjee M, Borawski J, Wolff A, King P, Einsele H, Leo E, Bargou RC.

Br J Haematol. 2010 May;149(4):529-36. doi: 10.1111/j.1365-2141.2010.08126.x. Epub 2010 Mar 13.

PMID:
20331455
31.

Oligomerized tumor necrosis factor-related apoptosis inducing ligand strongly induces cell death in myeloma cells, but also activates proinflammatory signaling pathways.

Berg D, Stühmer T, Siegmund D, Müller N, Giner T, Dittrich-Breiholz O, Kracht M, Bargou R, Wajant H.

FEBS J. 2009 Dec;276(23):6912-27. doi: 10.1111/j.1742-4658.2009.07388.x. Epub 2009 Nov 6.

32.

Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800.

Stühmer T, Chatterjee M, Grella E, Seggewiss R, Langer C, Müller S, Schoepfer J, Garcia-Echeverria C, Quadt C, Jensen MR, Einsele H, Bargou RC.

Br J Haematol. 2009 Nov;147(3):319-27. doi: 10.1111/j.1365-2141.2009.07852.x. Epub 2009 Aug 13.

PMID:
19686236
33.

Specific detection of CD56 (NCAM) isoforms for the identification of aggressive malignant neoplasms with progressive development.

Gattenlöhner S, Stühmer T, Leich E, Reinhard M, Etschmann B, Völker HU, Rosenwald A, Serfling E, Bargou RC, Ertl G, Einsele H, Müller-Hermelink HK.

Am J Pathol. 2009 Apr;174(4):1160-71. doi: 10.2353/ajpath.2009.080647. Epub 2009 Feb 26.

34.

Antitumoral and antileishmanial dioncoquinones and ancistroquinones from cell cultures of Triphyophyllum peltatum (Dioncophyllaceae) and Ancistrocladus abbreviatus (Ancistrocladaceae).

Bringmann G, Rüdenauer S, Irmer A, Bruhn T, Brun R, Heimberger T, Stühmer T, Bargou R, Chatterjee M.

Phytochemistry. 2008 Oct;69(13):2501-9. doi: 10.1016/j.phytochem.2008.06.019. Epub 2008 Aug 22.

PMID:
18723197
35.

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma.

Zöllinger A, Stühmer T, Chatterjee M, Gattenlöhner S, Haralambieva E, Müller-Hermelink HK, Andrulis M, Greiner A, Wesemeier C, Rath JC, Einsele H, Bargou RC.

Blood. 2008 Oct 15;112(8):3403-11. doi: 10.1182/blood-2007-11-119362. Epub 2008 Jul 17.

PMID:
18635812
36.

Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.

Stühmer T, Zöllinger A, Siegmund D, Chatterjee M, Grella E, Knop S, Kortüm M, Unzicker C, Jensen MR, Quadt C, Chène P, Schoepfer J, García-Echeverría C, Einsele H, Wajant H, Bargou RC.

Leukemia. 2008 Aug;22(8):1604-12. doi: 10.1038/leu.2008.111. Epub 2008 May 15.

PMID:
18480838
37.

[Heat shock protein 90 alpha und beta are overexpressed in multiple myeloma cells and critically contribute to survival].

Andrulis M, Chatterjee M, Jain S, Stühmer T, Ungethüm U, Kuban RJ, Lorentz H, Bommert K, Topp M, Kramer D, Müller-Hermelinks HK, Einsele H, Bargou RC, Greiner A.

Verh Dtsch Ges Pathol. 2007;91:330-7. German.

PMID:
18314631
38.

The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma.

Chatterjee M, Rancso C, Stühmer T, Eckstein N, Andrulis M, Gerecke C, Lorentz H, Royer HD, Bargou RC.

Blood. 2008 Apr 1;111(7):3714-22. Epub 2007 Nov 15.

PMID:
18006704
39.

Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells.

Janz M, Stühmer T, Vassilev LT, Bargou RC.

Leukemia. 2007 Apr;21(4):772-9. Epub 2007 Feb 1.

PMID:
17268519
40.

STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival.

Chatterjee M, Jain S, Stühmer T, Andrulis M, Ungethüm U, Kuban RJ, Lorentz H, Bommert K, Topp M, Krämer D, Müller-Hermelink HK, Einsele H, Greiner A, Bargou RC.

Blood. 2007 Jan 15;109(2):720-8. Epub 2006 Sep 26.

PMID:
17003370
41.

Signalling and survival pathways in multiple myeloma.

Bommert K, Bargou RC, Stühmer T.

Eur J Cancer. 2006 Jul;42(11):1574-80. Epub 2006 Jun 22. Review.

PMID:
16797970
42.

Selective pharmacologic activation of the p53-dependent pathway as a therapeutic strategy for hematologic malignancies.

Stühmer T, Bargou RC.

Cell Cycle. 2006 Jan;5(1):39-42. Epub 2006 Jan 26. Review.

PMID:
16322696
43.

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma.

Stühmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C, Theurich S, Cigliano L, Manz RA, Daniel PT, Bommert K, Vassilev LT, Bargou RC.

Blood. 2005 Nov 15;106(10):3609-17. Epub 2005 Aug 4.

PMID:
16081689
44.

Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells.

Chatterjee M, Stühmer T, Herrmann P, Bommert K, Dörken B, Bargou RC.

Blood. 2004 Dec 1;104(12):3712-21. Epub 2004 Aug 5.

PMID:
15297310
45.

Ectopic expression of the Dlx genes induces glutamic acid decarboxylase and Dlx expression.

Stühmer T, Anderson SA, Ekker M, Rubenstein JL.

Development. 2002 Jan;129(1):245-52.

46.

Expression from a Dlx gene enhancer marks adult mouse cortical GABAergic neurons.

Stühmer T, Puelles L, Ekker M, Rubenstein JL.

Cereb Cortex. 2002 Jan;12(1):75-85.

PMID:
11734534
47.

A highly conserved enhancer in the Dlx5/Dlx6 intergenic region is the site of cross-regulatory interactions between Dlx genes in the embryonic forebrain.

Zerucha T, Stühmer T, Hatch G, Park BK, Long Q, Yu G, Gambarotta A, Schultz JR, Rubenstein JL, Ekker M.

J Neurosci. 2000 Jan 15;20(2):709-21.

48.
49.

Opioid receptors from a lower vertebrate (Catostomus commersoni): sequence, pharmacology, coupling to a G-protein-gated inward-rectifying potassium channel (GIRK1), and evolution.

Darlison MG, Greten FR, Harvey RJ, Kreienkamp HJ, Stühmer T, Zwiers H, Lederis K, Richter D.

Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8214-9.

50.

Structure and pharmacological properties of a molluscan glutamate-gated cation channel and its likely role in feeding behavior.

Stühmer T, Amar M, Harvey RJ, Bermudez I, van Minnen J, Darlison MG.

J Neurosci. 1996 May 1;16(9):2869-80.

Supplemental Content

Loading ...
Support Center